CARCINOMATOUS MENINGITIS - ANTIBODY-GUIDED THERAPY WITH I-131 HMFG1

被引：19
|
作者：
MOSELEY, RP
BENJAMIN, JC
ASHPOLE, RD
SULLIVAN, NM
BULLIMORE, JA
COAKHAM, HB
KEMSHEAD, JT
机构：
[1] FRENCHAY HOSP, DEPT NEUROSURG, BRAIN TUMOR RES LAB, BRISTOL BS16 1LE, AVON, ENGLAND
[2] FRENCHAY HOSP, DEPT NEUROPATHOL, BRISTOL BS16 1LE, AVON, ENGLAND
[3] BRISTOL ROYAL INFIRM & GEN HOSP, CTR RADIOTHERAPY, BRISTOL BS2 8HW, AVON, ENGLAND
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 1991年 / 54卷 / 03期
关键词：
D O I：
10.1136/jnnp.54.3.260
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Seven patients with carcinomatous meningitis were administered intrathecal I-131 labelled monoclonal antibody HMFG1. Clinical responses were seen in two patients, with a long term survivor at 32 months. Aseptic meningitis occurred in 4/7 patients, but more serious toxicity was observed in the form of seizures (2/7 patients) and myelosuppression (3/7 patients). Partial obliteration of the subarachnoid space was identified as a potential problem in patients with advanced disease.
引用
收藏
页码：260 / 265
页数：6
相关论文
共 50 条
  • [21] CYTOPLASMIC REACTIVITY WITH THE MONOCLONAL-ANTIBODY HMFG1 AS A MARKER OF CERVICAL GLANDULAR ATYPIA
    BROWN, LJR
    GRIFFIN, NR
    WELLS, M
    JOURNAL OF PATHOLOGY, 1987, 151 (03): : 203 - &
  • [22] ABDOMINAL CT-SCAN VERSUS IMMUNOSCINTIGRAPHY WITH I-131 LABELED MOABHMFG2 AND HMFG1 (FAB')2 IN THE DETECTION OF RESIDUAL DISEASE IN OVARIAN-CANCER PATIENTS
    PECTASIDIS, D
    PATENIOTIS, K
    TZIMIS, L
    TRAPALI, X
    NATSIS, P
    ARAPANTONI, P
    PAPADIMITRIOU, JT
    EPENETOS, A
    ATHANASIOU, A
    KOUTSIOUBA, P
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1988, 14 (5-6): : 229 - 229
  • [23] THE TREATMENT OF INTRAPERITONEAL MALIGNANT DISEASE WITH MONOCLONAL-ANTIBODY GUIDED I-131 RADIOTHERAPY
    WARD, B
    MATHER, S
    SHEPHERD, J
    CROWTHER, M
    HAWKINS, L
    BRITTON, K
    GRANOWSKA, M
    SLEVIN, M
    BRITISH JOURNAL OF CANCER, 1987, 56 (05) : 701 - 702
  • [24] Human milk fat globule antigen 1 (HMFG1) expression in prostatic carcinoma and immunotargeting with a radiolabelled monoclonal anti-HMFG1 antibody
    Ljung, G
    Lennernäs, B
    Nordgren, H
    Holmberg, A
    Westlin, JE
    Nilsson, S
    Edgren, M
    ANTICANCER RESEARCH, 2000, 20 (04) : 2321 - 2324
  • [25] A STUDY OF ANTITUMOR ANTIBODY LABELED WITH I-131
    WISSLER, RW
    BARKER, PA
    FLAX, MH
    LAVIA, M
    TALMAGE, DW
    CANCER RESEARCH, 1955, 2 (01) : 53 - 54
  • [26] THE TREATMENT OF INTRAPERITONEAL MALIGNANT DISEASE WITH MONOCLONAL-ANTIBODY GUIDED I-131 RADIOTHERAPY
    WARD, B
    MATHER, S
    SHEPHERD, J
    CROWTHER, M
    HAWKINS, L
    BRITTON, K
    SLEVIN, ML
    BRITISH JOURNAL OF CANCER, 1988, 58 (05) : 658 - 662
  • [27] IMAGING OF CARCINOMA BY I-131 ANTIBODY TO CEA
    DELAND, FH
    KIM, EE
    BENNETT, S
    PRIMUS, FJ
    GOLDENBERG, DM
    JOURNAL OF NUCLEAR MEDICINE, 1978, 19 (06) : 693 - 693
  • [28] HYPOPARATHYROIDISM AFTER I-131 THERAPY
    FULOP, M
    ANNALS OF INTERNAL MEDICINE, 1971, 75 (05) : 808 - +
  • [29] THYROID CANCER AND THERAPY WITH I-131
    PIERS, DA
    LANCET, 1976, 2 (7981): : 373 - 373
  • [30] I-131 THERAPY FOR PAROTID ONCOCYTOMA
    KOSUDA, S
    ISHIKAWA, M
    TAMURA, K
    MUKAI, M
    KUBO, A
    HASHIMOTO, S
    JOURNAL OF NUCLEAR MEDICINE, 1988, 29 (06) : 1126 - 1129
12345